UCSF MIBG Protocol

Here are files for the UCSF Phase II high-activity 131I-MIBG compassionate use protocol for treatment of patients having malignant pheochromocytomas or paragangliomas.

In order for 131I-MIBG therapy to achieve a remission for patients with malignant pheochromocytoma, the tumors must have sufficient uptake of MIBG on diagnostic scans to allow enough 131I-MIBG to enter cells to radiate the cancer cell from within.    Treatment activities (doses) up to 500 mCi 131I-MIBG can be given without cryopreserved blood stem cells.  We have previously administered higher-activity  MIBG therapies, but that resulted in an increased risk for prolonged marrow suppression, such that peripheral blood stem cells were required to be collected and cryopreserved prior to ver high-activity MIBG therapy in case the bone marrow became severely suppressed and would not recover promptly.

This entry was posted in I-131-MIBG Treatment. Bookmark the permalink.

Comments are closed.